(Q48400649)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

0 references

1 reference

clinically isolated syndrome

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Luca Prosperini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Maria Puopolo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Nicola De Stefano

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Luisa Minghetti

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Emilia Sbardella

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Maria L Stromillo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Luca Ausili Cefaro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Patrizia Pantano

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Carlo Pozzilli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

23 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

411-417

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

Oxidative damage in multiple sclerosis lesions

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Isoprostanes as biomarkers and mediators of oxidative injury in infant and adult central nervous system diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

The Disability Status Scale for multiple sclerosis: apologia pro DSS sua.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

N-acetyl-L-aspartate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

The role of mitochondria in axonal degeneration and tissue repair in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

MR spectroscopy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

T2 lesions and rate of progression of disability in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Biomarkers of disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Bio-markers of disease activity and response to therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512457721

21 January 2018

Identifiers

DOI

10.1177/1352458512457721

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22917691%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference